<DOC>
	<DOCNO>NCT00064714</DOCNO>
	<brief_summary>This study determine 1 ) safety AC2993 patient type I diabetes ; 2 ) ability AC2993 improve beta cell function ; 3 ) effect immunosuppression beta cell function . Type I diabetes autoimmune disease , immune system attack beta cell pancreas . These cell produce insulin , regulate blood sugar . AC2993 may improve pancreas 's ability produce insulin help control blood sugar , may also activate original immune response cause diabetes . Thus , study examine effect AC2993 alone well combination immunosuppressive drug . Patients 18 60 year age type I diabetes mellitus may eligible 20-month study . They must diabetes least 5 year require insulin treatment . Candidates screen questionnaire , follow medical history physical examination , blood urine test , chest x-ray skin test tuberculosis , electrocardiogram ( EKG ) , arginine stimulate C-peptide test ( see description ) . Participants undergo follow test procedure : Advanced screen phase : Participants undergo diabetes education program , include instruction frequent blood glucose monitoring , dietary education count carbohydrate , intensive insulin therapy , review sign symptom low blood sugar ( hypoglycemia ) , potential treatment glucagon shot . Patients must administer insulin via insulin pump take least four injection per day include glargine ( Lantus ) insulin . 4-month run-in phase - Arginine-stimulated C-peptide test : This test measure body 's insulin production . The patient inject liquid contain arginine , normal constituent food increase insulin release beta cell blood stream . After injection , seven blood sample collect 10 minute . - Mixed meal stimulate C-peptide test acetaminophen : This test assess response beta cell ordinary meal time take food pas stomach . The patient drink food supplement take acetaminophen ( Tylenol ) . Blood sample draw catheter ( plastic tube place vein ) every 30 minute 4 hour measure level various hormone concentration acetaminophen . - Euglycemic clamp : This test measure body 's level insulin resistance measure amount glucose necessary compensate increase insulin level maintain prespecified blood glucose level .</brief_summary>
	<brief_title>Effect AC2993 With Without Immunosuppression Beta Cell Function Patients With Type I Diabetes</brief_title>
	<detailed_description>Type I diabetes mellitus ( T1DM ) typically result immune mediate destruction pancreatic beta cell . Previous study indicate patient retain capacity limit endogenous insulin production . AC2993 ( synthetic exendin-4 ) show preclinical human study several potentially beneficial antidiabetic action , include recovery neogenesis pancreatic islet . Thus , plan enroll adult long-standing T1DM C-peptide secretion indicate residual beta cell mass . The latter target AC2993 . Due possibility stimulate underlie autoimmune process T1DM , especially islet regeneration occur , subject half enrollee immunosuppression . We plan study effect AC2993 alone , immunosuppression ( daclizumab ) alone , well combination AC2993 immunosuppression insulin secretion glycemia control .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>INCLUSION CRITERIA : T1DM least 5 year define follow : 1 . Insulin dependence ( insulin requirement le 0.8 units/kg/day ) . 2 . Current past antiislet antibody ( antiinsulin initiation insulin therapy , antiislet cell ( ICA ) , antityrosine phosphatase IA2 , and/or antiglutamic acid decarboxylase ( GAD65 ) antibody ) . 3 . BMI great equal 20 kg/m ( 2 ) less equal 30 kg/m ( 2 ) . Cpeptide great equal 0.3 less equal 1.2 ng/mL baseline argininestimulated Cpeptide test . Age 18 60 year , inclusive . EXCLUSION CRITERIA : Symptomatic gastroparesis . Diabetic nephropathy creatinine clearance le 60 cc/min 24hour urine albumin great 300 mg. Insulin requirement great 0.8 units/kg/day . Hypoglycemia unawareness : Unless easily correct via simple modification patient 's diabetes regimen , potential enrollee exclude he/she suffer great equal 2 episode severe hypoglycemia recent 12 month , define require assistance third party , receive assistance medic , visit ER hospitalize due hypoglycemia . Evidence chronic infection . History malignancy . Any chronic medical condition unduly increase risk potential enrollee judge study investigator . Hematologic abnormality : 1 . Anemia ( hematocrit le 31.8 % woman le 36.7 % men ) . 2 . Leukopenia ( WBC count le 3.4 K/mm ( 3 ) ) . 3 . Thrombocytopenia ( platelet count le 162 K/mm ( 3 ) ) . Hypertension , whether untreated resistant medical treatment , blood pressure great 140/85 mm Hg . Pregnancy , breastfeed plan pregnancy within two year . Unable identify primary care provider willing partner study investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Type 1 Diabetes Mellitus ( T1DM )</keyword>
	<keyword>Beta-Cell</keyword>
	<keyword>C-Peptide</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Insulin</keyword>
	<keyword>Islet</keyword>
	<keyword>Function</keyword>
	<keyword>AC2993 ( Synthetic Exendin-4 )</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Type I Diabetes Mellitus</keyword>
	<keyword>T1DM</keyword>
</DOC>